HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: IGI

This article was originally published in The Rose Sheet

Executive Summary

IGI: Novasome lipid microvesicle manufacturer's first quarter consumer product sales grow about 38% to $1.2 mil., representing 13% of consolidated sales versus 7% of sales a year ago, the company said April 25. The firm attributed the improvement to an increase in product sales to Estee Lauder. The increase was also due to initial delivery sales of IGI's Nova Skin line to Glaxo Wellcome. Glaxo gained marketing rights to Nova Skin in January and relaunched it under the WellSkin brand, IGI said ("The Rose Sheet" Jan. 13, p. 2). Overall revenues climbed 9.9% to $9.5 mil., while net income advanced 31.5% to $363,000. The remainder of IGI's sales are generated from its animal health segment...

You may also be interested in...



OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Chart: Weekly Trademark Review -- Nov. 2, 2010

Weekly Trademark Review

UsernamePublicRestriction

Register

RS004140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel